Arrayit Corporation, a leading proprietary life science technology company focused on disease prevention and treatment, recently announced that the company won a competitive bid from the Centers for Disease Control (CDC) to manufacture devices designed to combat global bioterrorism. This contract will increase the CDC’s ability to decipher and combat bioterrorism on a global level.

Arrayit Corporation, headquartered in Sunnyvale, California, offers over 650 products to a customer base of more than 2,500 laboratories worldwide. This new contract from the CDC, granted on September 11, 2009, the eighth anniversary of the World Trade Center attacks, involves Arrayit Corporation’s proprietary peptide microarray manufacturing platform. The CDC will deploy the company’s peptide microarrays to create microarrays designed to combat infectious agents that pose a lethal threat in terrorist attacks.

Commenting on the contract, Rene Schena, chief executive officer and co-founder of Arrayit Corporation, stated, “We are pleased to be selected by the CDC for this competitive government contract. We look forward to leveraging the unique capabilities of our patented microarray platform to improve homeland security.”